More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer

(MedPage Today) -- Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news